Search | Clinical Trials Finder

Conditions: Ewings Sarcoma, Chemotherapy Induced Thrombocytopenia
Interventions: Romiplostim (AMG-531); Drug
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 1 Year and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 2
States / cities: Phoenix, Arizona • Cincinnati, Ohio

Conditions: Contraception, Breastfeeding
Interventions: Progestin Only Contraceptive Pills; Drug
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years and older · Female only
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Stroke
Interventions: Telerehabilitation; Device
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 2
States / cities: Los Angeles, California • Elkins Park, Pennsylvania

Conditions: Kidney Transplantation
Interventions: Kidney Biopsy, Rapamune (sirolimus/rapamycin), Tacrolimus; Procedure · Drug
Lead sponsor: University at Buffalo; Other
Eligibility: 18 Years and older
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Hepatitis B, Chronic
Interventions: peginterferon alfa-2a [Pegasys], tenofovir; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 2
States / cities: Los Angeles, California • San Francisco, California

Conditions: Chronic Lymphocytic Leukemia
Interventions: During Venetoclax; Drug
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 18 Years to 85 Years
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Healthy Diet, Stress, Pediatric Obesity, Intergenerational Relations
Interventions: Happy Family, Healthy Kids Program; Behavioral
Lead sponsor: Michigan State University; Other
Eligibility: 3 Years to 5 Years
Enrollment: 214 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Thompsonville, Michigan

Conditions: Locally Advanced Cervical Carcinoma
Interventions: Hypofractionated external beam radiation, Chemotherapy, Image-guided brachytherapy; Radiation · Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older · Female only
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Alzheimers Disease, Dementia, Alzheimers Disease, Familial
Interventions: E2814, Lecanemab, Matching Placebo (E2814); Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years to 80 Years
Enrollment: 197 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 12
States / cities: Birmingham, Alabama • La Jolla, California • Los Angeles, California + 9 more

Conditions: Community-acquired Pneumonia, Influenza, COVID-19
Interventions: Ceftriaxone, Moxifloxacin or Levofloxacin, Piperacillin-tazobactam, Ceftaroline, Amoxicillin-clavulanate, Standard course macrolide, Extended course macrolide, No systemic corticosteroid, Fixed-duration Hydrocortisone, Shock-dependent hydrocortisone, Fixed-duration higher dose Hydrocortisone, No antiviral agent for influenza, Five-days oseltamivir, Ten-days oseltamivir, No antiviral agent for COVID-19, Lopinavir / Ritonavir, Hydroxychloroquine, Hydroxychloroquine + lopinavir/ritonavir, Ivermectin, No immune modulation for COVID-19, Interferon beta-1a, Anakinra, Tocilizumab, Sarilumab, Local standard venous thromboprophylaxis, Therapeutic dose anticoagulation, Conventional low dose thromboprophylaxis, Intermediate dose thromboprophylaxis, Continuation of therapeutic dose anticoagulation, No immunoglobulin, Convalescent plasma, Delayed administration of convalescent plasma, No vitamin C, Vitamin C, No antiplatelet, Aspirin, P2Y12 inhibitor, No simvastatin, Simvastatin, Eritoran, Apremilast, Clinician-preferred mechanical ventilation strategy, Protocolised mechanical ventilation strategy, No renin-angiotensin system inhibitor, Angiotensin converting enzyme inhibitor, Angiotensin Receptor Blockers, ARB + DMX-200, No cysteamine, Cysteamine, Fixed-duration dexamethasone, Baloxavir Marboxil, Five-days oseltamivir + baloxavir marboxil, Ten-days oseltamivir + baloxavir marboxil, No endothelial modulator, Imatinib, No Immune Modulator for Influenza, Baricitinib, Nirmatrelvir/ritonavir, Remdesivir, Nirmatrelvir/ritonavir + remdesivir; Drug · Other · Biological + 1 more
Lead sponsor: UMC Utrecht; Other
Eligibility: 18 Years and older
Enrollment: 20,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2028
U.S. locations: 11
States / cities: Jacksonville, Florida • Augusta, Georgia • Chicago, Illinois + 8 more

Conditions: Cancer, Solid Tumor Cancer, Advanced Metastatic Cancer, Prostate, Small Cell Lung Cancer, Ovarian Cancer, Breast Cancer
Interventions: SYS6043; Drug
Lead sponsor: Conjupro Biotherapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 386 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 5
States / cities: Plantation, Florida • Austin, Texas • San Antonio, Texas + 1 more

Conditions: Solid Tumor
Interventions: [18F]FLT-PET/CT; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 8 Years to 25 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Head and Neck Cancer
Interventions: Radiotherapy, Leucovorin, Cetuximab, Filgrastim, Erythropoetin, Cisplatin, Fluorouracil, Docetaxel; Radiation · Drug · Biological
Lead sponsor: Drexel University College of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Pregnancy
Interventions: Immediate pushing, Delayed pushing; Procedure
Lead sponsor: Washington University School of Medicine; Other
Eligibility: Female only
Enrollment: 2,414 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2017
U.S. locations: 6
States / cities: Birmingham, Alabama • St Louis, Missouri • Portland, Oregon + 1 more

Conditions: Infant, Premature, Diseases
Interventions: Multisensory early oral administration of human milk; Other
Lead sponsor: Loyola University; Other
Eligibility: 23 Weeks to 32 Weeks
Enrollment: 125 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 2
States / cities: Maywood, Illinois

Conditions: Heart Failure
Interventions: LLM-GDMT Clinical Decision Support Tool; Device
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years to 85 Years
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Epidermal Growth Factor Receptor, Non-Small Cell Lung Cancer
Interventions: Erlotinib; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 3
States / cities: Boston, Massachusetts

Conditions: Graves' Disease
Interventions: Levothyroxine, Placebo; Drug · Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 70 Years
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: HIV Infections
Interventions: Patients elected to take licensed drugs. The vaccine was not provided for evaluation, multiple licensed drugs not randomized, multiple licensed antiretroviral drugs; not randomized, Intended vaccine not provided, Licensed drugs provided, but were not investigated; Drug · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 65 Years
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2013
U.S. locations: 1
States / cities: New York, New York

Conditions: Hepatitis B Infection
Interventions: Tenofovir Disoproxil Fumarate, Lamivudine Oral Solution; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 16 Years to 50 Years · Female only
Enrollment: 334 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Fanconi Anemia, Severe Aplastic Anemia, Myelodysplastic Syndromes, T Cell Receptor Alpha/Beta Depletion, Telomere Biology Disorder, Bone Marrow Failure, Dyskeratosis Congenita, Telomere Biology Disorders
Interventions: Total Body Irradiation (TBI) (Plan 1), Cyclophosphamide (CY) (Plan 1), Fludarabine (FLU), Methylprednisolone (MP), Donor mobilized PBSC infusion, G-CSF, Cyclophosphamide (CY) (Plan 2), Rituximab, Busulfan, Alemtuzumab, Melphalan; Drug · Device
Lead sponsor: Masonic Cancer Center, University of Minnesota; Other
Eligibility: Up to 65 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2029
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Maternal Dietary Diversity, Iron-Folic Acid Supplementation, Early Initiation of Breastfeeding
Interventions: Health Facility Level Interventions, Community Level Interventions, Health System Level Interventions; Behavioral
Lead sponsor: International Food Policy Research Institute; Other
Eligibility: 15 Years to 49 Years · Female only
Enrollment: 8,110 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Infant, Newborn, Hypertension, Pulmonary, Persistent Fetal Circulation Syndrome, Pneumonia, Aspiration, Respiratory Distress Syndrome, Newborn, Respiratory Insufficiency
Interventions: Inhaled Nitric Oxide, Standard iNO therapy; Drug
Lead sponsor: NICHD Neonatal Research Network; Network
Eligibility: Up to 14 Days
Enrollment: 302 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2003
U.S. locations: 18
States / cities: Birmingham, Alabama • Phoenix, Arizona • Palo Alto, California + 14 more

Conditions: Infant, Newborn, Respiratory Distress Syndrome, Respiratory Insufficiency
Interventions: Early surfactant, Standard practice; Drug
Lead sponsor: NICHD Neonatal Research Network; Network
Eligibility: Up to 12 Hours
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2002
U.S. locations: 13
States / cities: Birmingham, Alabama • Palo Alto, California • New Haven, Connecticut + 10 more

Search by objective public record fields.

Single Arm Romiplostim to Prevent CIT

Progestin-Only Pill Use and Breastfeeding Study

Telerehabilitation Early After Stroke

Kidney Biopsy Controlled Trial of Calcineurin Inhibitor Withdrawal

A Study of Early Immunologic Response in Asian Patients With Chronic Hepatitis B, Treated With Pegasys (Peginterferon Alfa-2a (40KD)), Nucleoside Analogues, or Both

Early Clonal Dynamics During Venetoclax Treatment for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

Happy Family, Healthy Kids Program

Accelerated Brachytherapy Forward Chemo Radiation Therapy (ABC-RT) for Locally-advanced Cervical Cancer

Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation (DIAN-TU)

Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia

Phase I Study of SYS6043 in Patients With Advanced/Metastatic Solid Tumors

Evaluation of [18F]FLT PET/CT as an Early Predictor of Outcome in Pediatric Solid Tumors

Induction Chemotherapy Followed by Cetuximab and Radiation Therapy for Head and Neck Cancer

Optimizing Management of the 2nd Stage of Labor: Multicenter Randomized Trial

Multisensory Early Oral Administration of Human Milk (M-MILK) for Very Preterm Infants

Targeted Artificial Intelligence Language mOdel Recommendations for Heart Failure (TAILOR-HF)

Rapid Plasma Genotyping For Early Initiation Of Erlotinib In EGFR Mutant Lung Cancer

Early Levothyroxine Post Radioactive Iodine

Controlling Acute or Early HIV Infection With Antiretroviral Drugs, Without a Candidate Vaccine.As Reported Previously, the Candidate Vaccie Was Not Provided by the Maufacturer as Promised

Reducing Vertical Transmission of Hepatitis B in Africa

Alpha/Beta TCD HCT in Patients With Inherited BMF Disorders

Assessing the Feasibility of Integrating a Package of Maternal Nutrition Interventions Into Antenatal Care Services in Burkina Faso

Early Inhaled Nitric Oxide for Respiratory Failure in Newborns

Early Surfactant to Reduce Use of Mechanical Breathing in Low Birth Weight Infants